Eradication therapy for Helicobacter pylori infection: Review of world trends


Cite item

Full Text

Abstract

The literature review gives current views on the treatment of Helicobacter pylori infection. The rising antibiotic resistance of H. pylori in the first decade of the 21st century entailed the decreased efficiency of common eradication therapy (ET) regimens, by determining the higher interest in this problem. The paper summarizes data on the efficiency of current ET regimens in different regions of the world in the past 3 years. The prospects of alternative ET regimens are considered. The existing and promising ways of optimizing the current ET regimens are presented.

Full Text

Эрадикационная терапия инфекции Helicobacter pylori: обзор мировых тенденций. - Аннотация. В обзоре литературе представлены современные взгляды на лечение инфекции Helicobacter pylori. Рост антибиотикорезистентности H. pylori в первое десятилетие XXI века повлек за собой снижение эффективности распространенных схем эрадикационной терапии (ЭТ), определяя повышенный интерес к данной проблеме. В статье суммированы и проанализированы данные об эффективности современных схем ЭТ в различных регионах мира за последние 3 года. Рассматриваются перспективы альтернативных схем ЭТ. Приводятся существующие и перспективные пути оптимизации современных схем ЭТ.
×

References

  1. Ruggiero P. Helicobacter pylori infection: what's new. Curr Opin Infect Dis 2012; 25 (3): 337-344.
  2. Tonkic A., Tonkic M., Lehours P., Mégraud F. Epidemiology and diagnosis of Helicobacter pylori infection. Helicobacter 2012; 17 (Suppl. 1): 1-8.
  3. Shmuely H., Katicic M., Filipec Kanizaj T., Niv Y. Helicobacter pylori and nonmalignant diseases. Helicobacter 2012; 17 (Suppl. 1): 22-25.
  4. Huang X., Qu X., Yan W. et al. Iron deficiency anaemia can be improved after eradication of Helicobacter pylori. Postgrad Med J 2010; 86 (1015): 272-278.
  5. Stasi R., Sarpatwari A., Segal J.B. et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood 2009; 113 (6): 1231-1240.
  6. Malfertheiner P., Megraud F., O'Morain C. et al.; European Helicobacter Study Group. Management of Helicobacter pylori infection: the Maastricht IV/ Florence Consensus Report. Gut 2012; 61 (7): 646-664.
  7. Ивашкин В.Т., Маев И.В., Лапина Т.Л. и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Рос журн гастроэнтерол гепатол, колопроктол 2012; 1: 87-89.
  8. De Francesco V., Ierardi E., Hassan C., Zullo A. Helicobacter pylori therapy: Present and future. World J Gastrointest Pharmacol Ther 2012; 3 (4): 68-73.
  9. Georgopoulos S.D., Papastergiou V., Karatapanis S. Helicobacterpylori eradication therapies in the era of increasing antibiotic resistance: A paradigm shift to improved efficacy. Gastroenterol Res Pract 2012; 2012: 757926.
  10. Tepes B., O'Connor A., Gisbert J., O'Morain C. Treatment of Helicobacter pylori infection 2012. Helicobacter 2012; 17 (Suppl. 1): 36-42.
  11. Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 1374-1384.
  12. De Francesco V., Giorgio F., Hassan C. et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010; 19 (4): 409-414.
  13. Elviss N.C., Owen R.J., Breathnach A. et al. Helicobacter pylori antibiotic-resistance patterns and risk factors in adult dyspeptic patients from ethnic diverse populations in central and south London during 2000. J Med Microbiol 2005; 4: 567-574.
  14. Pajares García J.M., Pajares-Villarroya R., Gisbert J.P. Helicobacter pylori infection: antibiotic resistance. Rev Esp Enferm Dig 2007; 99 (2): 63-70.
  15. Glupczynski Y., Megraud F., Lopez-Brea M. et al. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001; 20: 820-823.
  16. Megraud F., Coenen S., Versporten A. et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62 (1): 34-42.
  17. Кудрявцева Л.В. Состояние антибиотикорезистентности Helicobacter pylori в России. Экспер клин гастроэнтерол 2003; 3: 4-5.
  18. Маев И.В., Самсонов А.А., Андреев Д.Н. и др. Современные аспекты диагностики и лечения инфекции Helicobacter pylori (по материалам консенсуса Маастрихт IV, Флоренция, 2010). Мед совет 2012; 8: 10-19.
  19. Rimbara E., Fischbach L.A., Graham D.Y. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol 2011; 8: 79-88.
  20. Gisbert J.P., Pajares R., Pajares J.M. Evolution of Helicobacter pylori therapy from a meta-analytical perspective. Helicobacter 2007;12 (Suppl. 2): 50-58.
  21. Gisbert J.P., Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther 2011; 34 (11): 1255-1268.
  22. Yoon J.H., Baik G.H., Sohn K.M. et al. Trends in the eradication rates of Helicobacter pylori infection for eleven years. World J Gastroenterol 2012; 18 (45): 6628-6634.
  23. Fujioka T., Aoyama N., Sakai K. et al. A large-scale nationwide multicenter prospective observational study of triple therapy using rabeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in Japan. J Gastroenterol 2012; 47 (3): 276-283.
  24. Dore M.P., Farina V., Cuccu M. et al. Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days. Helicobacter 2011; 16 (4): 295-300.
  25. Xu M.H., Zhang G.Y., Li C.J. Efficacy of bismuth-based quadruple therapy as first-line treatment for Helicobacter pylori infection. Zhejiang Da Xue Xue Bao Yi Xue Ban 2011; 40 (3): 327-331.
  26. Essa A.S., Kramer J.R., Graham D.Y., Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter 2009; 14 (2): 109-118.
  27. Gisbert J.P., Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol 2012; 5: 23-34.
  28. Yanai A., Sakamoto K., Akanuma M. et al. Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized study in Japan. World J Gastrointest Pharmacol Ther 2012; 3 (1): 1-6.
  29. Hassan C., De Francesco V., Zullo A. et al. Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy. Aliment Pharmacol Ther 2003; 18: 641-646.
  30. Francavilla R., Lionetti E., Castellaneta S.P. et al. Improved efficacy of 10-day sequential treatment for Helicobacter pylori eradication in children: a randomized trial. Gastroenterol 2005; 129: 1414-1419.
  31. Delgado J., Bujanda L., Gisbert P. et al. Effectiveness of a 10-day sequential treatment for Helicobacter pylori eradication in clinical practice. Gastroenterology 2007; 132: A112.
  32. Schmilovitz-Weiss H., Shalev T., Chechoulin Y. et al. High eradication rates of Helicobacter pylori infection following sequential therapy: the Israeli experience treating naïve patients. Helicobacter 2011; 16 (3): 229-233.
  33. Kim Y.S., Kim S.J., Yoon J.H. et al. Randomized clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. Aliment Pharmacol Ther 2011; 34 (9): 1098-1105.
  34. Tsay F.W., Tseng H.H., Hsu P.I. et al. Sequential therapy achieves a higher eradication rate than standard triple therapy in Taiwan. J Gastroenterol Hepatol 2012; 27 (3): 498-503.
  35. Kate V., Kalayarasan R., Ananthakrishnan N. Sequential therapy versus standard triple-drug therapy for helicobacter pylori eradication: a systematic review of recent evidence. Drugs 2013; 73 (8): 815-824.
  36. Wu D.C., Hsu P.I., Tseng H.H. et al. Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies. Medicine (Baltimore) 2011; 90: 180-185.
  37. Gisbert J.P. "Rescue" regimens after Helicobacter pylori treatment failure. World J Gastroenterol 2008; 14: 5385-5402.
  38. Chuah S.K., Tsay F.W., Hsu P.I., Wu D.C. A new look at anti-Helicobacter pylori therapy. World J Gastroenterol 2011; 17 (35): 3971-3975.
  39. Berning M., Krasz S., Miehlke S. Should quinolones come first in Helicobacter pylori therapy? Ther Adv Gastroenterol 2011; 4 (2): 103-114.
  40. Gisbert J.P., Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006; 23 (1): 35-44.
  41. Wong W.M., Gu Q., Chu K.M. et al. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006; 23: 421-427.
  42. Kuo C.H., Hu H.M., Kuo F.C. et al. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. J Antimicrob Chemother 2009; 63: 1017-1024.
  43. Miehlke S., Krasz S., Schneider-Brachert W. et al. Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. Helicobacter 2011; 16 (6): 420-426.
  44. Savarino V., Zentilin P., Pivari M. et al. The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. Aliment Pharmacol Ther 2000; 14 (7): 893-900.
  45. Hsu P.I., Wu D.C., Chen A. et al. Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures. Eur J Clin Invest 2008; 38 (6): 404-409.
  46. Gisbert J.P., Calvet X., Bujanda L. et al. "Rescue" therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter 2003; 8 (2): 90-94.
  47. Apseloff G. Severe neutropenia among healthy volunteers given rifabutin in clinical trials. Clin Pharmacol Ther 2003; 74 (6): 591-592.
  48. Treiber G., Ammon S., Malfertheiner P., Klotz U. Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures. Helicobacter 2002; 7 (4): 225-231.
  49. Basu P.P., Rayapudi K., Pacana T. et al. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol 2011; 106 (11): 1970-1975.
  50. Hsu P.I., Wu D.C., Wu J.Y., Graham D.Y. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter 2011; 16 (2): 139-145.
  51. Ma H.J., Wang J.L. Quadruple therapy for eradication of Helicobacter pylori. World J Gastroenterol 2013; 19 (6): 931-935.
  52. Karatapanis S., Georgopoulos S.D., Papastergiou V. et al. 7, 10 and 14-days rabeprazole-based standard triple therapies for H. pylori eradication: are they still effective? A randomized trial. Acta Gastroenterol Belg 2011; 74 (3): 407-412.
  53. Villoria A. Acid-related diseases: are higher doses of proton pump inhibitors more effective in the treatment of Helicobacter pylori infection? Gastroenterol Hepatol 2008; 31: 546-547.
  54. Кучерявый Ю.А., Баркалова Е.В. Двойные дозы ингибиторов протонной помпы - путь повышения эффективности тройной антихеликобактерной терапии первого ряда. Леч дело 2012; 1: 36-42.
  55. Uygun A., Ozel A.M., Sivri B. et al. Efficacy of a modified sequential therapy including bismuth subcitrate as first-line therapy to eradicate Helicobacter pylori in a Turkish population. Helicobacter 2012; 17 (6): 486-490.
  56. Kuo C.H., Kuo F.C., Hu H.M. et al. The Optimal First-Line Therapy of Helicobacter pylori Infection in Year 2012. Gastroenterol Res Pract 2012; 2012: 168361.
  57. Pinchuk I.V., Bressollier P., Verneuil B. et al. In vitro anti-Helicobacter pylori activity of the probiotic strain Bacillus subtilis 3 is due to secretion of antibiotics. Antimicrob Agents Chemother 2001; 45 (11): 3156-3161.
  58. Zou J., Dong J., Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter 2009; 14 (5): 97-107.
  59. Szajewska H., Horvath A., Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010; 32 (9): 1069-1079.
  60. Wang Z.H., Gao Q.Y., Fang J.Y. Meta-Analysis of the Efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol 2013; 47 (1): 25-32.
  61. Li G., Li L., Yu C., Chen L. Effect of vitamins C and E supplementation on Helicobacter pylori eradication: a meta-analysis. Br J Nutr 2011; 106 (11): 1632-1637.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies